Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
NEW YORK--(BUSINESS WIRE) December 29, 2022 -- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 29, 2022 Category: Pharmaceuticals Source Type: clinical trials

Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022. Clearmind Medicine Inc. (“Clearmind” or the " company " ), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 28, 2022 Category: Pharmaceuticals Source Type: clinical trials

U.S. FDA Accepts for Review the Biologics License Application for Pfizer ’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine NEW YORK--(BUSINESS WIRE) December 28, 2022 -- Pfizer Inc. (NYSE:PFE) today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 28, 2022 Category: Pharmaceuticals Source Type: clinical trials

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA
SHANGHAI and HONG KONG, Dec. 27, 2022. Antengene Corporation Limited ( " Antengene " ), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 27, 2022 Category: Pharmaceuticals Source Type: clinical trials

New Drug Application for RiVive Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA
PITTSBURGH, Dec. 26, 2022. Harm Reduction Therapeutics (HRT), Inc., a 501(c)(3) nonprofit pharmaceutical company whose mission is to prevent opioid overdose deaths by making free or low-cost over-the-counter (OTC) naloxone nasal spray available to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 26, 2022 Category: Pharmaceuticals Source Type: clinical trials

Immuron Receives FDA Approval for Travelan IND Application
MELBOURNE, Australia, Dec. 23, 2022.Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 23, 2022 Category: Pharmaceuticals Source Type: clinical trials

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage
Condition:   Sub-arachnoid Haemorrhage Interventions:   Drug: Levosimendan;   Other: Placebo Sponsors:   Assistance Publique - Hôpitaux de Paris;   Orion Corporation, Orion Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials